Acumen Pharmaceuticals, Inc. Q3 FY2026 earnings call

• Phase II AltitudeAD Trial: Management confirmed that top-line results for the Phase II trial of Sobernitog (Subirnatug) are expected in November. The study tests the central thesis that arresting harm from synaptotoxic amyloid beta-oligomers offers a differentiated Alzheimer’s treatment. The trial is well-powered with clinically meaningful endpoints, testing two doses (35 mg/kg and 50 mg/kg) against placebo over 18 months.
• Pipeline Advancement (EBD Program): The Enhanced Brain Delivery (EBD) program continues to advance, representing the only approach combining blood-brain barrier penetration technology with an A-beta-oligomer-selective antibody. Two candidates, ACU301 and ACU401, are in development ahead of an IND filing expected in mid-2027. Recent data presented at AAIC showed ACU401 achieved up to 40-fold greater frontal cortex exposure in non-human primates compared to unmodified antibodies.
• Operational Execution: The AltitudeAD trial demonstrated high operational standards, including rapid enrollment and strong patient retention, with over 95% of eligible participants rolling into the open-label extension.
• Financial Position: The company ended Q3 2026 with approximately $79 million in cash and marketable securities, sufficient to fund operations into early 2027. R&D expenses were $21.1 million (down year-over-year due to lower manufacturing/CRO costs), and D&A expenses were $4.7 million. The net loss for the quarter was $25.4 million.

As a pre-commercial clinical-stage biopharmaceutical company, Acumen Pharmaceuticals does not have distinct product segments generating revenue. Consequently, there is no revenue contribution percentage or absolute sales performance to report. The company's financials reflect operational expenses associated with its research and development pipeline.

• Top-Line Data Release: Management expects to announce the top-line results of the Phase II AltitudeAD trial in November 2026.
• Clinical Success Threshold: The company is guiding toward a minimum clinical success metric of a 30% slowing on the Idris scale after 18 months compared to placebo as the basis for moving forward to Phase III.
• Safety Expectations: Management anticipates low double-digit ARIA rates consistent across genotypes, supporting the safety profile required for Phase III advancement.
• Future Development: No specific guidance was provided for Phase III start dates, but management indicated that positive Phase II results would lead to a single confirmatory Phase III trial.

• Binary Clinical Outcome Risk: The upcoming Phase II readout is a critical milestone; failure to meet the efficacy threshold (30% slowing on Idris) could halt development of Sobernitog.
• Scientific Hypothesis Risk: The trial tests a novel scientific thesis targeting soluble oligomers rather than plaques. If the oligomer hypothesis is not validated by this data, the entire strategic direction may need reassessment.
• Regulatory and Development Timeline: Delays in obtaining IND approval for EBD candidates (expected mid-2027) or negative safety signals (such as higher-than-expected ARIA rates) could impact future pipeline progression.
• Cash Runway: While current cash supports operations into early 2027, continued reliance on equity financing may be required if clinical timelines extend or additional capital is needed for Phase III initiation.

Q: Bank of America asked how Subirnatug might fit into evolving treatment paradigms, specifically as a maintenance therapy after plaque clearance by agents like Donanemab, and whether Altitude data informs this.

A: CEO Daniel O'Connell stated that chronic dosing during stable early AD stages is logical because soluble aggregates persist. He confirmed it would be a natural extension to use Subirnatug as a post-plaque-clearance follow-on, though the primary focus remains establishing Phase III readiness via the 18-month primary endpoint.

Q: Stifel asked about dose selection rationale and expected differences between the 35 mg/kg and 50 mg/kg doses in terms of efficacy and safety.

A: Management explained that doses were selected based on Phase 1 exposure and pharmacodynamic modeling, placing both within an efficacious zone. They noted the higher 50 mg/kg dose might show stronger effects on amyloid PET signals, but emphasized both doses offer an attractive benefit-risk profile.

Q: Cantor Fitzgerald asked for the 'bar' for success to move to Phase III, particularly regarding clinical scales, biomarkers, and OLE data availability.

A: Management reiterated the 30% slowing on Idris as the key efficacy threshold. They clarified that while the Open Label Extension (OLE) will generate evidence through 2027, the top-line November readout will include primary/secondary efficacy, safety (including ARIA), and fluid/imaging biomarkers (like p-tau217) to support Phase III decision-making.

Q: BTIG asked if Subirnatug’s mechanism allows for faster action, potentially enabling shorter Phase III trials, and how the study is set up to capture such effects.

A: O'Connell acknowledged that high selectivity for toxic oligomers suggests the drug could neutralize species rapidly, allowing earlier time points to establish drug effect. However, he stated the current Altitude design is a robust test of the hypothesis, and they are eagerly awaiting unblinding to interpret these dynamics.

Q: Lucid Capital Markets asked about patient retention impacting primary analysis and the timeline for initiating subcutaneous (SC) formulation work.

A: Management reported retention exceeded expectations with high rollover to the OLE. Regarding SC formulation, they completed a bioavailability study in healthy volunteers in early 2025 and plan to incorporate a subcutaneous option in Phase III, potentially analogous to strategies used by competitors.